NCT05272384View on ClinicalTrials.gov

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

June 28, 2027

Study Completion Date

June 28, 2027

Conditions
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Hodgkin Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Decitabine and Cedazuridine

Given PO

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (9)

10016

RECRUITING

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

11501

RECRUITING

NYU Langone Hospital - Long Island, Mineola

35233

SUSPENDED

University of Alabama at Birmingham Cancer Center, Birmingham

60451

RECRUITING

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

RECRUITING

University of Chicago Medicine-Orland Park, Orland Park

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

06520

RECRUITING

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH